EJPMR, 2026, 13(2), 445-452 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

A SCIENTIFIC REVIEW OF HYPERLIPIDEMIA IN PERSPECTIVE OF AYURVEDA

[1]*Dr. Seema V. Rathod, MD (Kayachikitsa), [2]Dr. Gunvant H. Yeola, MD, PhD (Kayachikitsa)

[1]Associate Professor, Department of Kayachikitsa, Dr. Rajendra Gode Ayurved College and Research Center, Amravati and PhD Scholar, Department of Kayachikitsa, Dr. D. Y. Patil College of Ayurved and Research Center, (Deemed to be University) Pimpri, Pune, India.
[2]Professor, Department of Kayachikitsa, Director of International Collaboration, Dr. D. Y. Patil College of Ayurved and Research Center (Deemed to be University), Pimpri, Pune, India.

***Corresponding Author: Dr. Seema V. Rathod**

MD (Kayachikitsa), Associate Professor, Department of Kayachikitsa, Dr. Rajendra Gode Ayurved College and Research Center, Amravati and PhD Scholar, Department of Kayachikitsa, Dr. D. Y. Patil College of Ayurved and Research Center, (Deemed to be University) Pimpri, Pune, India.

DOI: https://doi.org/10.5281/zenodo.18596015

How to cite this Article: [1]*Dr. Seema V. Rathod, MD (Kayachikitsa), [2]Dr. Gunvant H. Yeola, MD, PhD (Kayachikitsa) (2026). A Scientific Review Of Hyperlipidemia In Perspective Of Ayurveda 2026). European Journal of Pharmaceutical and Medical Research, 13(2), 445–452.

Article Received on 15/01/2026 **Article Revised on 05/02/2026** **Article Published on 10/02/2026**

ABSTRACT

Hyperlipidemia, characterized by elevated serum levels of lipids such as cholesterol and triglycerides, is a major modifiable risk factor for cardiovascular diseases (CVDs) and metabolic disorders globally. While the term "hyperlipidemia" does not directly appear in the classical Ayurvedic literature, correlated pathological concepts—particularly *Meda Dhatu* imbalance and *Medovaha Srotodushti*—have long been discussed in classical texts. It is a major risk factor for cardiovascular diseases (CVD), metabolic syndrome, and related morbidity/mortality. Modern medicine uses statins and lifestyle modification but these have limitations and side effects. Ayurveda offers traditional conceptualization and management strategies that are being validated by modern research. This research paper synthesizes classical Ayurvedic texts, modern pathophysiological understandings, and recent clinical studies to explore the etiology, pathogenesis, diagnostic approaches, and therapeutic strategies for hyperlipidemia drawing from ancient
scriptures like *Charaka Samhita*, *Sushruta Samhita*, and *Ashtanga Hridaya*, alongside contemporary research.

KEYWORDS: Hyperlipidemia, *Meda*, Ayurveda.

INTRODUCTION

Hyperlipidemia, or dyslipidemia, refers to abnormal elevations in blood lipids, including cholesterol, triglycerides, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), often accompanied by reduced high-density lipoprotein (HDL). Globally, it affects over 39% of adults, contributing to 2.6 million deaths annually from cardiovascular diseases (CVDs). In India, prevalence ranges from 25-30% in urban areas to 15-20% in rural populations, exacerbated by sedentary lifestyles, dietary shifts, and genetic factors.[1]

In Ayurveda, hyperlipidemia correlates with *Medoroga* or *Medodosha*, where excessive *Meda Dhatu* accumulation disrupts metabolic harmony. *Charaka Samhita* describes *Sthaulya* as a *Santarpanajanya Vikara* (disease from over-nourishment), involving vitiated *Kapha Dosha*, impaired *Agni*, and *Ama* (toxins) formation.

Hyperlipidemia has become a public health concern worldwide because of its association with atherosclerosis, coronary artery disease, stroke, and metabolic syndrome. Traditional medicine systems like Ayurveda offer holistic approaches that focus on root causes (samprapti) rather than only symptomatic management. While classical Ayurvedic texts do not explicitly employ the term "hyperlipidemia," scholars and clinicians have correlated it with conditions such as Medoroga, Atisthaulya, *Rasa-Raktagata Sneha Vriddhi*, and various forms of *Meda Dhatu* vitiation, especially

Medovaha Srotodushti (pathology of the lipid-transporting channels)

OBJECTIVES

1. To elucidate Ayurvedic concepts of hyperlipidemia.
2. To correlate Ayurvedic pathophysiology with modern lipid metabolism.
3. To classify and evaluate Ayurvedic interventions based on evidence.
4. To discuss clinical applications, limitations, and future prospects.

CONCEPTUAL FRAMEWORK IN AYURVEDA

Ayurvedic Principles and Lipid Metabolism[2]

Ayurveda defines health as a state of equilibrium among doshas, dhatus (tissues), malas (waste products), and agni (digestive/metabolic fire). The dhatu *Meda* corresponds broadly to adipose tissue and lipids in modern physiology. It plays roles in energy storage, lubrication, and insulation of the body.

According to Ayurvedic physiology, the formation and maintenance of Meda depend on:

- Upadhatus and *Agnis* (digestive and tissue-level metabolic fire)
- Balanced doshas, especially Kapha, which is closely linked with *Meda* due to its Snigdha (unctuous), Guru (heavy) qualities.

Classical texts describe that disturbance in digestion (*Agnimandya*) and consequent accumulation of *Ama* (toxic undigested metabolic byproducts) leads to aberrant Meda formation and deposition in tissues and channels.

Medovaha Srotas and Srotodushti

The channels carrying Meda (*Medovaha Srotas*) can become dysfunctional through Kapha overgrowth, Ama accumulation, and impaired Agni. This pathological state is referred to as *Medovaha Srotodushti*. Although ancient authors did not describe "hyperlipidemia" per se, this concept reflects disturbances in lipid metabolism and distribution, analogous to elevated serum lipid levels seen in modern medicine.

Correlation with Hyperlipidemia

Modern hyperlipidemia is defined biochemically as elevated total cholesterol, LDL-cholesterol, triglycerides, or reduced HDL-cholesterol. In Ayurvedic terms.

- **Atypical accumulation of Meda** due to metabolic imbalance aligns with **elevated lipid profiles**
- **Santarpana (excessive nourishment)** leading to *Kapha* and *Meda* aggravation parallels sedentary lifestyle and high-fat dietary patterns implicated in hyperlipidemia
- Persistent imbalance resulting in downstream pathology (e.g., *Hrdroga* or heart disease) mirrors complications of dyslipidemia in modern medicine.

The classical Sanskrit phrase *Yatah Samhṛta Meda Dhatu* (excessive Meda tissue) can be analogized to hyperlipidemia and related metabolic disorders, Lipid metabolism involves exogenous (dietary) and endogenous pathways. Chylomicrons transport dietary lipids, while VLDL from the liver carries endogenous ones. Hyperlipidemia types include familial (genetic defects in lipoprotein lipase) and acquired (obesity, diabetes). Ayurvedically, this parallels *Bhutagni Paka* (elemental digestion) in the liver (*Yakrit*), where *Sara* (nutritive) and *Kitta* (waste) separate.[3]

In FCS, severe hypertriglyceridemia (>1000 mg/dL) causes pancreatitis, correlating with *Kapha-Pitta Dushti* in *Rasa-Raktavaha Srotas*.[4]

Table 1: Ayurvedic and Modern Correlation of Hyperlipidemia.

Ayurvedic Concept	Description	Modern Biomedical Correlate
Meda Dhatu Vriddhi	Excess fat tissue accumulation	Obesity, adiposity
Agni Mandya	Impaired digestive/metabolic fire	Reduced metabolic rate, insulin resistance
Ama	Toxic undigested metabolites	Oxidized LDL, inflammatory mediators
Srotodushti	Obstruction in channels	Endothelial dysfunction, impaired lipid transport
Kapha Prakopa	Dosha imbalance promoting heaviness	Anabolic, lipid-accumulating state
Lekhana & Medoghna therapy	Fat-reducing interventions	Lipid-lowering, anti-inflammatory effects

CLASSICAL EVIDENCE IN AYURVEDIC TEXTS

Ayurveda views lipids as part of *Meda Dhatu*, derived from *Mamsa Dhatu* (muscle tissue) through *Dhatvagni* (tissue metabolism). *Meda* is *Snigdha* (unctuous), *Guru* (heavy), and dominated by *Prithvi* and *Apa Mahabhutas* (earth and water elements). Hyperlipidemia is akin to *Asthayi Meda Vriddhi* (unstable lipid increase), leading to *Srotodushti* (channel blockage).

Nidana Panchaka Applied to Hyperlipidemia

A. Nidana (Etiological Factors)

Classical Ayurvedic texts identify multiple etiological factors that directly correspond to modern risk factors for hyperlipidemia. These include.

1. Ahara Nidana (Dietary Factors)

- Excessive intake of *Snigdha* (unctuous), *Guru* (heavy), *Madhura* (sweet), and *Abhishyandi* foods
- Frequent consumption of dairy products, fried foods, refined carbohydrates, and excessive calories
- Irregular eating habits and overeating

These dietary patterns promote **Kapha and Meda vriddhi** and suppress Agni, leading to improper lipid metabolism.

2. Vihara Nidana (Lifestyle Factors)
- Sedentary lifestyle (*Avyayama*)
- Excessive sleep (*Atinidra*), especially daytime sleep
- Lack of physical exertion
- Chronic mental stress and emotional eating

These factors reduce metabolic demand and contribute to lipid accumulation.

3. Manasika Nidana (Psychological Factors)
- Stress (*Chinta*), anxiety, and depression
- Hedonic eating patterns

Ayurveda recognizes the influence of psychological factors on Agni and metabolism, anticipating modern psychosomatic concepts.

Table 2: Nidana (Etiological Factors) and Contemporary Risk Factors.

Ayurvedic Nidana	Classical Description	Modern Equivalent / Risk Factor
Ahara Nidana	Excess snigdha, guru, madhura	High-fat diet, refined carbs
Vihara Nidana	Sedentary lifestyle, excessive sleep	Physical inactivity, sedentary behavior
Manasika Nidana	Chinta, stress	Chronic stress, emotional eating
Santarpana	Over-nutrition, overfeeding	Positive energy balance, obesity

B. Purvarupa (Prodromal Features)

The early manifestations of Meda and Kapha imbalance include.
- Lethargy and heaviness of the body
- Excessive sleep
- Reduced appetite or irregular digestion
- Mild breathlessness on exertion
- Excessive sweating

These symptoms often precede detectable biochemical abnormalities and indicate early metabolic dysfunction.

C. Rupa (Clinical Features)

Once the disease is fully manifested, the clinical features reflect systemic Meda dysfunction:
- Central obesity or disproportionate fat accumulation
- Reduced physical endurance
- Heaviness and stiffness of the body
- Excessive thirst and sweating
- Predisposition to associated disorders such as *Prameha* (diabetes) and *Hridroga* (cardiac disorders)

In many cases, hyperlipidemia remains asymptomatic until complications arise, a fact acknowledged in Ayurveda through descriptions of silent progression of Santarpanajanya Vyadhi.

D. Upashaya–Anupashaya (Therapeutic Response Patterns)

Ayurveda recognizes diagnostic clues based on response to interventions:
- Improvement with *Langhana*, *Deepana*, *Lekhana*, and exercise
- Worsening with heavy food intake, inactivity, and excessive rest

This therapeutic response pattern reinforces the Kapha–Meda dominance in hyperlipidemia.

E. Samprapti (Pathogenetic Sequence)

Pathogenesis (Samprapti): Impaired *Jatharagni* leads to *Ama* formation, combining with *Meda* to cause *Medovaha Srotodushti*. This manifests as *Kshudra Shwasa* (dyspnea), *Alasya* (lethargy), *Swedadhikya* (excess sweating), and complications like *Prameha* (diabetes) or *Hridroga* (heart disease).[5]

Though not explicitly termed “hyperlipidemia,” the classical Ayurvedic canon (Charaka, Sushruta, Vagbhata) discusses *Meda*, its normal physiology, and conditions of excess (*Meda Vriddhi*) and imbalance. Classical references in bruhatrayee are as follows.
- *Charaka Samhita* (Sutra 21/4-9): *Sthaulya* as over-nourishment disease.
- *Sushruta Samhita* (Sutra 15): *Atisthula* with excessive *Meda*.
- *Ashtanga Hridaya* (Sutra 14): Similar features.

a. Fundamental Ayurvedic Etiology

In Ayurveda, hyperlipidemia is not identified by a single modern medical term but is primarily correlated with Medoroga (disorder of fat tissue), Medovaha Srotodusti (vitiation of fat-carrying channels), and Bahu Abaddha Medas (excessive unbound fat). It is considered a Santarpanjanya Vyadhi, a disease caused by over-nutrition and metabolic sluggishness.

Meda Dhatu is one of the seven primary tissues (*Sapta Dhatus*) responsible for fatty tissue formation, energy storage, and lubrication. Excessive Meda is described under *Medoroga* and *Sthaulya*, often associated with perturbation of *Kapha dosha* due to imbalanced diet and lifestyle.

Classical authors emphasize that balanced *Medas* are essential for strength and vitality, but **excessive Meda** predisposes to systemic imbalance.

The pathophysiology of hyperlipidemia is driven by imbalances in the body's functional energies (Doshas), tissues (Dhatus), and metabolic fire (Agni).

- **Agni (Metabolic Fire):** Impairment of Jatharagni (central digestive fire) leads to Agnimandya (weak digestion), which results in

the formation of Ama—toxic, undigested metabolic waste. Specifically, a hypofunction of Medo-Dhatwagni (the metabolic fire of adipose tissue) fails to properly process fat, leading to its abnormal accumulation.

- **Ama (Metabolic Toxins):** Ama is sticky and unctuous, similar in nature to cholesterol. It circulates through the bloodstream and clogs the body's channels (**Srotas**), leading to metabolic stagnation.

- **Dosha Imbalance**
  - **Kapha:** An excess of Kapha Dosha, which shares properties of heaviness and unctuousness with fat, is the primary driver.
  - **Pitta:** Imbalanced Pitta affects fat digestion and the metabolic transformation of lipids.
  - **Vata:** In later stages, accumulated fat can block the movement of Vata (**Avarana**), leading to severe complications and increased functional burden on the heart.

b. The Pathogenetic Process (Samprapti)

The Ayurvedic progression of hyperlipidemia follows a specific sequence of metabolic failure:

1. **Indulgence in Causative Factors:** Frequent consumption of heavy (*Guru*), oily (*Snigdha*), and sweet (*Madhura*) foods, combined with a sedentary lifestyle (*Avyayama*) and day-sleeping (*Divasvapna*).
2. **Formation of Ama-Rasa:** Impaired Agni converts food into an immature, excessively sweet, and unctuous essence called Ama-Rasa.
3. **Abnormal Fat Accumulation:** This essence is readily converted into Meda Dhatu (fat tissue) due to its similar qualities. However, because the metabolic fire for fat (Medo-Dhatwagni) is weak, this fat is "morbid" or "unbound" (*Abaddha Meda*).
4. **Srotorodha (Channel Obstruction):** Excess morbid fat clogs the microchannels (Srotas), particularly the Medovaha Srotas.
5. **Dhatu Depletion:** Because the channels are blocked by fat, other essential tissues (like bone or muscle) are deprived of nutrition, leading to a state where only fat increases while overall body strength and vitality decrease.

c. Samprapti Flow of Hyperlipidemia in Ayurveda

[Excess Ahara & Avyayama]
↓
Agni Mandya
↓
Ama Formation
↓
Kapha Prakopa
↓
Meda Dhatu Vriddhi
↓
Medovaha Srotodushti
↓
Clinical Hyperlipidemia
↓
Complications (Hridroga, Prameha)

Above samprapti Shows correlation with modern pathophysiology.

diet/lifestyle\
↓
metabolic impairment
↓
lipid accumulation
↓
cardiovascular/metabolic complications.

MODERN PATHOPHYSIOLOGICAL CORRELATION

Pathological Consequences

- **Avarana:** The morbid fat eventually blocks the normal flow of Vata Dosha (*Medasavrita Vayu*), which can lead to life-threatening conditions like cardiovascular disease, stroke, or severe exhaustion.
- **Physical Symptoms:** Clinical manifestations include pendulous abdomen or breasts (*Chala Sphika-Udar-Stana*), excessive sweating (*Swedadhikya*), breathlessness on exertion (*Kshudra Shwasa*), and lethargy (*Utsahahani*).
- **Atherosclerotic Plaques:** Ayurveda describes a process similar to plaque formation where morbid Meda, due to its "cement-like" nature (earth and water elements), adheres to the walls of the channels, obstructing blood flow.

Lipid metabolism involves exogenous (dietary) and endogenous pathways. Chylomicrons transport dietary lipids, while VLDL from the liver carries endogenous ones. Hyperlipidemia types include familial (genetic defects in lipoprotein lipase) and acquired (obesity, diabetes). Ayurvedically, this parallels *Bhutagni Paka* (elemental digestion) in the liver (*Yakrit*), where *Sara* (nutritive) and *Kitta* (waste) separate.[6]

In FCS, severe hypertriglyceridemia (>1000 mg/dL) causes pancreatitis, correlating with *Kapha-Pitta Dushti* in *Rasa-Raktavaha Srotas*.[7]

DIFFERENTIAL DIAGNOSIS IN AYURVEDA

Ayurveda distinguishes hyperlipidemia-like states from:

- **Sthaulya** – Primarily obesity with Meda dominance
- **Prameha** – Metabolic disorder with carbohydrate and lipid dysregulation
- **Hridroga** – Cardiovascular disease as a complication

Hyperlipidemia may exist independently or as a precursor to these conditions

PROGNOSTIC CONSIDERATIONS (SADHYA–ASADHYATA)

Classical texts caution that Santarpanajanya disorders become **Krichra-Sadhya** (difficult to cure) if lifestyle modification is neglected. Chronicity, age, associated

comorbidities, and patient compliance influence prognosis—principles echoed in modern chronic disease management.

AYURVEDIC THERAPEUTICS

Ayurvedic management of hyperlipidemia is based on the principle that disease arises from metabolic imbalance rather than isolated biochemical abnormalities. Therefore, treatment aims not merely at reducing lipid values but at restoring Agni, eliminating Ama, correcting Dosha imbalance, and normalizing Meda Dhatu metabolism. Classical texts emphasize that sustainable management of Santarpanajanya Vyadhi requires a comprehensive therapeutic approach integrating Ahara (diet), Vihara (lifestyle), Aushadha (medicines), and Shodhana (purificatory therapies).

Hyperlipidemia, being predominantly a Kapha–Meda disorder, demands therapies possessing Lekhana (scraping), Medoghna (fat-reducing), Kaphaghna, and Deepana–Pachana properties.

a) Ahara (Dietary Management)

Pathya Ahara

Dietary regulation forms the cornerstone of Ayurvedic therapy in Meda disorders. Classical texts repeatedly emphasize that no medicine can be effective if dietary indiscretions persist. The primary goals of Ahara in hyperlipidemia are:

- Reduction of Kapha and Meda
- Stimulation of Agni
- Prevention of Ama formation

Recommended dietary qualities include

- **Laghu (light)**
- **Ruksha (dry)**
- **Ushna (hot)**
- **Katu, Tikta, Kashaya Rasa** dominance

Foods such as barley (*Yava*), millet, green gram, leafy vegetables, bitter gourds, and spices like ginger, black pepper, and turmeric are traditionally advocated.

Apathya Ahara

Foods to be avoided include:

- Excessive fats, oils, dairy products
- Refined carbohydrates and sweets
- Processed and fried foods
- Excessive alcohol

These foods aggravate Kapha and Meda and suppress Agni, directly contributing to lipid dysregulation.

b) Vihara (Lifestyle Modification)

Physical Activity (Vyayama)

Classical Ayurveda strongly advocates **regular physical exercise** as a primary therapeutic measure in Sthaulya and Meda disorders. Vyayama enhances Agni, mobilizes stored Meda, improves circulation, and balances Kapha.
The extent of exercise should be individualized based on age, strength, and disease severity, aligning with modern recommendations for personalized lifestyle medicine.

Behavioral and Sleep Regulation

Avoidance of daytime sleep (*Divaswapna*), excessive rest, and sedentary behavior is emphasized. Proper sleep hygiene and stress management are considered essential to maintain metabolic balance.

c) Aushadha Chikitsa (Pharmacological Management)

Dravyaguna Perspective

Ayurvedic drugs used in hyperlipidemia typically possess the following attributes:

- **Rasa**: Katu, Tikta, Kashaya
- **Guna**: Laghu, Ruksha
- **Virya**: Ushna
- **Vipaka**: Katu

These properties counteract Kapha and Meda accumulation and promote lipid mobilization.

d) Single Herbs with Hypolipidemic Potential

1. Guggulu[8] (Commiphora mukul)

Guggulu is the most extensively studied Ayurvedic drug for lipid disorders. Classical texts describe it as *Medohara* and *Lekhana*. Modern studies attribute its lipid-lowering action to guggulsterones, which modulate cholesterol metabolism and bile acid excretion.

2. Garlic[9] (Allium sativum)

Garlic is described as *Deepana*, *Pachana*, and *Hridya*. Clinical trials demonstrate its ability to reduce total cholesterol and LDL while exerting antioxidant and anti-inflammatory effects.

3. Triphala[10]

A classical polyherbal formulation with mild laxative, antioxidant, and metabolic regulatory effects. Triphala supports Agni and reduces Ama, indirectly improving lipid profiles.

e) Classical Formulations

1 Navaka Guggulu[11]

Comprising Guggulu with Triphala and Trikatu, Navaka Guggulu is traditionally prescribed in Medoroga. Clinical studies report significant reductions in total cholesterol, LDL, and triglycerides.

2 Arogyavardhini Vati[12]

This formulation acts on hepatic metabolism and is beneficial in dyslipidemia associated with fatty liver disease. Its Deepana–Pachana and Medoghna actions are well documented.

3 Mustadi Ghanavati[13]

Randomized controlled trials have shown improvement in lipid profiles and body composition with Mustadi Ghanavati, attributed to its Kapha-reducing and metabolic enhancing properties.

Drug / Formulation	Classical Property	Active Constituents	Modern Evidence / Effect
Guggulu[8](Commiphora mukul)	Medohara, Lekhana	Guggulsterones	↓Total cholesterol, ↓LDL, anti-inflammatory
Garlic[9] (Allium sativum)	Deepana, Pachana, Hridya	Allicin, S-allyl cysteine	↓Total cholesterol, ↓LDL, antioxidant
Triphala[10]	Agni-vardhaka, Ama-pachana	Polyphenols, tannins	↓Cholesterol, antioxidant, hepatic protective
Navaka Guggulu[11]	Medohara, Kapha-pacifying	Polyherbal	↓LDL, ↓Triglycerides, ↑HDL
Arogyavardhini Vati[12]	Medoghna, Deepana	Metallic-herbal	Improved lipid profile, hepatic function

f) Panchakarma and Shodhana Therapies

1 Role of Shodhana

Classical texts recommend **Shodhana** (bio-purification) in chronic and severe Meda disorders. Shodhana aims to eliminate accumulated Doshas and Ama from their root, preventing recurrence.

2 Virechana (Therapeutic Purgation)

Virechana is particularly indicated in Pitta-Kapha disorders involving Meda and Rakta. It improves lipid metabolism by enhancing hepatic function and clearing metabolic toxins.

3 Lekhana Basti

Medicated enemas with Lekhana and Kaphaghna drugs have shown promising results in reducing lipid parameters and body fat in clinical studies.

g) Rasayana and Preventive Approach

Ayurveda emphasizes **Rasayana therapy** for long-term metabolic health. Drugs such as *Amalaki* and *Guduchi* support metabolic resilience, antioxidant defense, and cardiovascular health, making them valuable adjuncts in hyperlipidemia management.

h) Integrative Therapeutic Model

The Ayurvedic therapeutic model for hyperlipidemia can be summarized as.

- **Correction of Agni**
- **Elimination of Ama**
- **Reduction of Kapha and Meda**
- **Normalization of Srotas function**
- **Sustained lifestyle modification**

This multi-layered approach contrasts with single-target pharmacotherapy and aligns with modern systems biology perspectives.

Multi-target therapeutic actions of Ayurveda



AYURVEDIC AND MODERN CORRELATION OF HYPERLIPIDEMIA

Ayurvedic Concept	Description	Modern Biomedical Correlate
Meda Dhatu Vriddhi	Excess fat tissue accumulation	Obesity, adiposity
Agni Mandya	Impaired digestive/metabolic fire	Reduced metabolic rate, insulin resistance
Ama	Toxic undigested metabolites	Oxidized LDL, inflammatory mediators
Srotodushti	Obstruction in channels	Endothelial dysfunction, impaired lipid transport
Kapha Prakopa	Dosha imbalance promoting heaviness	Anabolic, lipid-accumulating state
Lekhana & Medoghna therapy	Fat-reducing interventions	Lipid-lowering, anti-inflammatory effects

Strengths of the Ayurvedic Approach

Key strengths identified through this review include:

1. **Holistic disease understanding** encompassing physical, behavioral, and metabolic factors
2. **Individualized treatment** based on constitution (*Prakriti*) and disease stage
3. **Strong preventive orientation** emphasizing diet and lifestyle
4. **Multi-dimensional therapeutics** acting on digestion, metabolism, and inflammation
5. **Cultural acceptability and accessibility** in many populations

These strengths position Ayurveda as a valuable component of integrative cardiometabolic care.

Limitations and Challenges

Despite promising conceptual and clinical correlations, several limitations must be acknowledged.

1 Scientific Limitations

- Many clinical studies on Ayurvedic drugs have **small sample sizes**
- Heterogeneity in formulations, dosage, and duration complicates meta-analysis
- Limited availability of large, multicenter randomized controlled trials

2 Methodological Challenges

- Difficulty in translating qualitative Ayurvedic parameters into quantitative outcomes
- Variability in raw drug quality and lack of universal standardization
- Limited mechanistic studies bridging molecular biology and classical concepts

3Clinical Integration Issues

- Need for practitioner training in integrative models
- Potential herb–drug interactions requiring careful supervision
- Regulatory and policy barriers in some healthcare systems

Addressing these challenges is essential for the responsible integration of Ayurveda into mainstream lipid management.

Future Research Directions

Based on the findings of this review, future research should focus on.

1. **Large-scale randomized controlled trials** using standardized Ayurvedic formulations
2. **Mechanistic studies** exploring molecular pathways of Medoghna and Lekhana drugs
3. **Biomarker-based research** correlating Agni, Ama, and inflammation
4. **Comparative effectiveness studies** between Ayurveda, conventional therapy, and integrative approaches
5. **Long-term safety and pharmacovigilance studies**
6. **Systems biology and omics-based approaches** to interpret Ayurvedic polyherbal actions

Such research efforts would strengthen the evidence base and facilitate global acceptance of Ayurvedic interventions.

DISCUSSION

Hyperlipidemia is increasingly recognized as a complex, multifactorial metabolic disorder involving not only lipid abnormalities but also chronic inflammation, oxidative stress, insulin resistance, and endothelial dysfunction. The present review demonstrates that Ayurveda offers a coherent and holistic framework for understanding these processes through its concepts of Meda Dhatu, Kapha Dosha, Agni, Ama, and Srotas.

One of the most significant strengths of the Ayurvedic model lies in its process-oriented understanding of disease (Samprapti). Rather than focusing solely on laboratory-defined thresholds of cholesterol or triglycerides, Ayurveda conceptualizes lipid imbalance as the outcome of long-standing dietary excess, sedentary behavior, impaired digestion, and metabolic inefficiency. This perspective aligns closely with contemporary views that hyperlipidemia is a manifestation of systemic metabolic dysfunction rather than an isolated biochemical defect.

Classical descriptions of Santarpanajanya Vyadhi are particularly relevant, as they anticipate modern lifestyle-related disorders by emphasizing over-nutrition, physical inactivity, and chronic disease progression. The observation that individuals with excessive Meda may simultaneously exhibit reduced strength and vitality reflects modern insights into sarcopenic obesity and metabolically unhealthy phenotypes.

CONCLUSION

Hyperlipidemia represents a growing global health challenge driven by lifestyle changes, metabolic dysfunction, and chronic inflammation. Ayurveda, though developed in a pre-biochemical era, provides a remarkably sophisticated and relevant framework for understanding and managing lipid disorders through the concepts of Meda Dhatu imbalance, Agnimandya, Ama accumulation, and Medovaha Srotodushti.

This comprehensive review demonstrates that Ayurvedic principles and therapeutics are conceptually aligned with modern scientific understanding of lipid metabolism and cardiovascular risk. Emerging experimental and clinical evidence supports the efficacy and safety of selected Ayurvedic interventions when used judiciously.

The integration of Ayurveda with modern medicine—grounded in scientific validation, standardization, and clinical prudence—holds significant promise for developing holistic, preventive, and sustainable approaches to hyperlipidemia and associated metabolic disorders.

REFERENCES

1. http://ej-med.org/index.php/ejmed/article/download/815/486
2. Bhatted S, Vyas M, Harti SK, Nesari TM, Kumar A (2022) A Comparative Study of 7 Ayurveda Interventions to Control Dyslipidemia Using Meta Data. Curr Res Cmpl Alt Med, 6: 157. DOI: 10.29011/2577-2201.100057
3. Chiranjit Biswas, Supriyo Chaudhuri, Tapan Ghosh. Concept of Hyperlipidemia in Ayurveda. AYUSHDHARA, 2022; 9(1): 55-62. https://doi.org/10.47070/ayushdhara.v9i1.863
4. Jadhav SS. Ayurveda in the management of infant hyperlipidemia: A case report. J Ayurveda Integr Med, 2022 Apr-Jun; 13(2): 100517. doi:10.1016/j.jaim.2021.08.010. Epub 2021 Nov 27. PMID:34844842; PMCID:PMC8728053.

5. Chiranjit Biswas, Supriyo Chaudhuri, Tapan Ghosh. Concept of Hyperlipidemia in Ayurveda. AYUSHDHARA, 2022; 9(1): 55-62. https://doi.org/10.47070/ayushdhara.v9i1.863
6. Chiranjit Biswas, Supriyo Chaudhuri, Tapan Ghosh. Concept of Hyperlipidemia in Ayurveda. AYUSHDHARA, 2022; 9(1): 55-62. https://doi.org/10.47070/ayushdhara.v9i1.863
7. Jadhav SS. Ayurveda in the management of infant hyperlipidemia: A case report. J Ayurveda Integr Med, 2022 Apr-Jun; 13(2): 100517. doi: 10.1016/j.jaim.2021.08.010. Epub 2021 Nov 27. PMID: 34844842; PMCID: PMC8728053.
8. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia. JAMA, 2003; 290(6): 765–72.
9. Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders. Nutr J., 2002; 1: 4.
10. Panda S, Kar A. Triphala lowers lipid levels in hypercholesterolemic rats. Phytother Res, 2007; 21(8): 739–41.
11. Gupta AK, Mishra R. Clinical evaluation of Navaka Guggulu in Medoroga. AYU, 2012; 33(3): 355–60.
12. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery. Nat Rev Drug Discov, 2009; 8(10): 804–11.
13. Gupta AK, Mishra R. Clinical evaluation of Mustadi Ghanavati in dyslipidemia. AYU, 2013; 34(2): 123-8.